Endometriosis and Heart Disease: The Cardiovascular Connection Nobody Is Explaining

Women with endometriosis face a cardiovascular burden that remains invisible in standard gynecologic care. A 2024 Danish nationwide cohort study of 114,000 women published in the European Heart Journal found that endometriosis confers a 35% elevated risk of acute myocardial infarction (adjusted HR 1.35) and an 18% increased risk of ischemic stroke (adjusted HR 1.18), with a 40-year cumulative incidence of major cardiovascular events reaching 17.5% versus 15.3% in unaffected women. Kim et al. 2024 These risks emerge in the reproductive years and compound silently across decades.

The Twenty-Year Silence

She spent twenty years managing endometriosis symptoms. She never once heard it mentioned in the same conversation as her heart. A 2023 meta-analysis says it should have been.

I see her versions constantly. The 42-year-old referred for atypical chest pain. The 38-year-old with unexplained hypertension. The 51-year-old presenting with her first non-ST-elevation myocardial infarction. When I take histories, the endometriosis diagnosis emerges as an afterthought. Multiple laparoscopies. Hormonal suppression for a decade. Maybe a hysterectomy at 39. They mention it the way they mention an old ankle sprain.

They do not know it is relevant. Neither, apparently, do many of their physicians.

Endometriosis affects approximately 190 million women globally. That is 10% of reproductive-age women. The condition has been classified for a century as a gynecologic disorder. Painful periods. Infertility. Pelvic adhesions. The frame has been anatomically local. The reality is systemically inflammatory.

The Nurses’ Health Study II tracked 116,430 women for over two decades. Women with laparoscopically confirmed endometriosis had a 52% higher risk of myocardial infarction compared to women without the diagnosis (HR 1.52; 95% CI 1.17-1.98). They had a 35% higher risk of coronary artery bypass grafting or angioplasty (HR 1.35; 95% CI 1.08-1.69). Mu et al. 2016 These associations held after adjusting for smoking, BMI, and other traditional risk factors. 5 / Solid

The cardiovascular signal is not subtle. It is being missed because nobody is looking.

The Inflammation That Never Turns Off

Endometriosis is not contained to the pelvis. The lesions are local. The immune response is not.

Women with endometriosis have significantly elevated serum levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). A 2017 study in the Journal of Clinical Endocrinology & Metabolism measured a mean TNF-α difference of +2.3 pg/mL (p<0.001) and a mean IL-6 difference of +1.8 pg/mL (p<0.001) compared to controls. Santoro et al. 2017 These are not esoteric research markers. These are the cytokines that drive arterial inflammation.

The mechanism is direct. TNF-α and IL-6 impair endothelial nitric oxide synthase (eNOS) activity. Nitric oxide is the molecule that keeps arteries relaxed and resistant to plaque formation. When eNOS function drops, arteries stiffen. Flow-mediated dilation decreases. In women with endometriosis, studies have measured an average reduction in flow-mediated dilation of 4.2% compared to age-matched controls. Scientific Reports 2024 That number represents measurable vascular dysfunction in women still in their thirties. 4 / Promising

The inflammatory cascade does not wait for menopause. It begins at diagnosis. It compounds with every year the disease remains active.

This is what I call the Endometriosis Vascular Debt. The inflammation accumulates interest. The body pays later, in coronary events, in strokes, in premature arterial aging. By the time traditional cardiovascular risk factors appear on a screening panel, the vascular damage has been accruing for two decades.

High-sensitivity C-reactive protein (hs-CRP) is the accessible clinical marker for this process. It is not routinely measured in women with endometriosis. It should be. A hs-CRP above 2 mg/L signals elevated cardiovascular risk regardless of LDL cholesterol. In women with endometriosis, I recommend baseline measurement at diagnosis and annual monitoring thereafter. For more on this marker, see hs-CRP inflammation and heart disease in women.

The Lipid Pattern That Hides

Traditional lipid panels miss what is happening in endometriosis.

A cross-sectional analysis from the Nurses’ Health Study II found that women with endometriosis had significantly lower HDL cholesterol (mean 58.7 vs. 61.2 mg/dL, p<0.001) and higher triglycerides (mean 115.3 vs. 104.8 mg/dL, p<0.001) compared to women without the diagnosis. These differences persisted after adjusting for BMI and physical activity. The LDL numbers looked similar between groups.

This is the problem. The LDL looks fine. The lipid panel comes back “normal.” But the atherogenic pattern is there if you know where to look.

The triglyceride-to-HDL ratio is a better signal. A ratio above 3.5 indicates insulin resistance and small, dense LDL particles. These are the particles that penetrate arterial walls and seed atherosclerotic plaques. Standard lipid panels do not report this ratio. You have to calculate it.

Apolipoprotein B (ApoB) is the superior marker. Each atherogenic particle carries exactly one ApoB molecule. The ApoB count tells you the true number of particles hitting your arterial walls, not just the cholesterol they carry. An ApoB above 100 mg/dL indicates elevated cardiovascular risk even when LDL appears acceptable. In women with endometriosis-associated dyslipidemia, ApoB often reveals what the standard panel conceals.

Lipoprotein(a) adds another layer. Lp(a) is genetically determined and confers independent cardiovascular risk. Its levels do not respond to lifestyle changes. Approximately 20% of the population has elevated Lp(a). In women with endometriosis who already carry inflammatory risk, an elevated Lp(a) compounds the burden. Testing once is sufficient since levels remain stable over life.

The test panel I request for every woman with endometriosis: standard lipid panel plus ApoB, Lp(a), hs-CRP, and fasting insulin. This provides a complete picture. The standard panel alone does not.

The Surgical Menopause Cascade

Here is where the cardiovascular picture becomes more complicated.

Many women with severe endometriosis eventually undergo hysterectomy, often with bilateral salpingo-oophorectomy. When the ovaries are removed before natural menopause, surgical menopause begins abruptly. The cardiovascular consequences are distinct from those of natural menopause and more severe.

The Nurses’ Health Study stroke analysis examined this directly. Women with endometriosis had a 34% higher stroke risk overall. But hysterectomy with oophorectomy explained 39% of that excess risk. Postmenopausal hormone therapy explained another 16%. Saeed et al. 2022 The surgery intended to treat the disease created its own cardiovascular penalty. 5 / Solid

Women who undergo bilateral oophorectomy before age 45 without estrogen replacement face an accelerated trajectory of cardiovascular risk. See surgical menopause cardiovascular crash for the complete clinical picture. The abrupt loss of endogenous estrogen removes vascular protection at an age when natural menopause would not occur for another decade. The arteries age faster. The risk curves shift.

This does not mean surgery should be avoided when medically indicated. It means the cardiovascular implications must be part of the preoperative discussion. Hormone therapy decisions must weigh vascular protection against other considerations. Cardiovascular monitoring must intensify after surgical menopause, not remain at pre-surgical baselines.

Women don’t die from what they have. Women die from what they hold.

The woman with endometriosis holds two decades of inflammatory burden. If she undergoes surgical menopause, she holds the additional burden of abrupt estrogen loss. If nobody measures her cardiovascular markers, if nobody discusses these risks, if nobody adjusts her monitoring, she holds the burden of what was never explained.

The Guideline Gap

The NICE guideline NG73 on endometriosis, updated in 2024, recognizes endometriosis as a chronic systemic disease requiring ongoing care. It does not include cardiovascular screening recommendations. The American College of Obstetricians and Gynecologists practice bulletin on endometriosis does not mention cardiovascular risk. The European Society of Human Reproduction and Embryology guidelines do not include cardiac surveillance.

This is a gap between evidence and practice that has not been closed.

The evidence base is now substantial. Multiple large prospective cohorts. Meta-analyses. Biological mechanism studies. The 2024 Danish nationwide cohort in the European Heart Journal represents level 1 evidence of association. The 40-year cumulative incidence data (17.5% vs 15.3% for major cardiovascular events) translates to a meaningful absolute risk difference in a young population.

The clinical infrastructure is not in place. Gynecologists managing endometriosis do not have cardiovascular risk assessment in their standard workflow. Primary care physicians may not recognize endometriosis history as a cardiovascular risk modifier. Cardiologists rarely ask about endometriosis when taking reproductive histories.

The patient falls into the gap.

I am not suggesting endometriosis requires cardiology referral at diagnosis. I am suggesting that women with endometriosis need to understand their risk profile and that primary care must incorporate cardiovascular surveillance into ongoing management. Blood pressure at every visit. Lipid panels starting at diagnosis, not waiting for age-based screening thresholds. Inflammatory markers tracked over time. Explicit discussion of how surgical decisions affect vascular risk.

The condition shares biological pathways with other hormone-mediated cardiovascular risk modifiers. Women with polycystic ovary syndrome face similar inflammatory and metabolic burdens. See PCOS cardiovascular risk in women. Women with premature ovarian insufficiency or early menopause face accelerated vascular aging. See early menopause cardiovascular risk. The reproductive system and the cardiovascular system are not separate. They are connected through inflammation, through estrogen, through the immune architecture that governs both.

Autoimmune conditions, which share biological pathways with endometriosis, also confer independent cardiovascular risk. See autoimmune cardiac risk in women. The pattern is consistent. Chronic inflammation, wherever it originates, taxes the vasculature. The heart does not care whether the inflammation began in the pelvis, the joints, or the thyroid. It responds to the cytokine burden.

The Monitoring Framework

Here is what cardiovascular surveillance should look like for a woman with endometriosis.

At diagnosis, regardless of age: baseline blood pressure, fasting lipid panel with calculated triglyceride-to-HDL ratio, ApoB, hs-CRP, and fasting insulin. Document Lp(a) once. Establish baseline weight and waist circumference.

Annually thereafter: blood pressure at every clinical encounter. Repeat fasting lipid panel and hs-CRP yearly. Fasting insulin every 1-2 years depending on initial results.

Before any surgical decision involving oophorectomy: explicit discussion of cardiovascular implications. If oophorectomy proceeds and the patient is under 50, consider referral for cardiovascular risk stratification. Hormone therapy decision should include vascular protection as a weighted factor.

At menopause, whether surgical or natural: reassess complete cardiovascular risk profile. Consider coronary artery calcium scoring if risk factors have accumulated. Optimize lipid management to targets appropriate for inflammatory disease.

The thresholds are not different from standard cardiovascular prevention. The timing is different. A 35-year-old woman without endometriosis might reasonably defer aggressive lipid management. A 35-year-old woman with endometriosis and elevated hs-CRP has already been carrying inflammatory vascular burden for a decade. Her timeline is not the same.

The Conversation That Should Happen

I want women with endometriosis to walk into their next appointment with specific requests.

Not “Should I be worried about my heart?” That question is too easy to dismiss. The answer will be generic reassurance.

Ask instead: “Given my endometriosis diagnosis and the evidence from the Nurses’ Health Study and the 2024 European Heart Journal cohort, I would like baseline cardiovascular risk assessment. Can we order ApoB, Lp(a), hs-CRP, and fasting insulin in addition to a standard lipid panel?”

Print this article. Hand it to your physician if needed. The evidence is here. The citations are here. The request is specific and defensible.

If you are facing a decision about hysterectomy with oophorectomy, ask: “Can we discuss how surgical menopause affects cardiovascular risk specifically? What are the implications for hormone therapy decisions? How should my cardiac surveillance change after this surgery?”

If you have already undergone surgical menopause for endometriosis and nobody has discussed these issues with you, the conversation is overdue but not too late. Request the testing. Establish baselines now. Begin monitoring.

The cardiovascular connection exists. The evidence is solid. The clinical implementation is lagging. You do not have to wait for guidelines to catch up.

Frequently Asked Questions

Does endometriosis actually increase heart disease risk?

The evidence is now substantial and consistent across multiple large studies. The Nurses’ Health Study II, following 116,430 women prospectively, found that women with laparoscopically confirmed endometriosis had a 52% higher risk of myocardial infarction compared to women without the diagnosis. This association held after adjusting for smoking, BMI, oral contraceptive use, and other confounders. A 2024 Danish nationwide cohort study of 114,000 women published in the European Heart Journal confirmed a 35% elevated risk of acute myocardial infarction (adjusted HR 1.35) persisting across 40 years of follow-up. The 40-year cumulative incidence of major cardiovascular events (heart attack plus ischemic stroke) was 17.5% in women with endometriosis versus 15.3% in women without. This is level 1 evidence of association from prospective cohort data.

Why does endometriosis affect the heart?

Endometriosis drives chronic systemic inflammation that extends far beyond the pelvic lesions. Women with the condition have elevated serum levels of pro-inflammatory cytokines including TNF-alpha and IL-6. These cytokines directly impair endothelial nitric oxide synthase, the enzyme that keeps arteries relaxed and resistant to plaque formation. Studies have measured a 4.2% reduction in flow-mediated dilation in women with endometriosis compared to age-matched controls. This represents measurable vascular dysfunction in women still in their reproductive years. The estrogen dysregulation characteristic of endometriosis compounds the vascular damage. The inflammatory and hormonal mechanisms create a pro-atherogenic and pro-thrombotic state that accumulates cardiovascular risk over decades before traditional risk factors become apparent.

Should women with endometriosis get cardiac screening?

Current clinical guidelines, including NICE NG73 and ACOG practice bulletins, do not include cardiovascular screening recommendations for women with endometriosis. This represents a gap between the epidemiological evidence and clinical practice. Given the magnitude of risk elevation demonstrated in multiple large cohort studies, women with endometriosis should request baseline cardiovascular assessment at diagnosis rather than waiting for age-based screening thresholds. This includes thorough lipid panels with ApoB, inflammatory markers including hs-CRP, and fasting insulin. Blood pressure should be monitored at every clinical encounter. The goal is to detect subclinical cardiovascular risk while it is still modifiable, not to wait until traditional risk factors emerge in the perimenopausal years.

Does surgical treatment for endometriosis change heart risk?

Surgical treatment itself does not worsen cardiovascular risk. However, when surgery includes bilateral oophorectomy before natural menopause, the resulting surgical menopause carries distinct cardiovascular consequences. The Nurses’ Health Study stroke analysis found that women with endometriosis had a 34% higher stroke risk, and hysterectomy with oophorectomy explained 39% of that excess risk. The abrupt loss of endogenous estrogen removes vascular protection at an age when natural menopause would not occur for another decade. This does not mean oophorectomy should be avoided when medically indicated. It means the cardiovascular implications must be part of preoperative counseling, hormone therapy decisions must include vascular protection as a consideration, and cardiovascular monitoring must intensify after surgical menopause.

What tests should I ask for if I have endometriosis?

Request a thorough cardiovascular risk panel that goes beyond the standard lipid panel. The specific tests are: ApoB (apolipoprotein B), which counts the actual number of atherogenic particles rather than just cholesterol content; Lp(a) (lipoprotein a), which is genetically determined and confers independent risk; hs-CRP (high-sensitivity C-reactive protein), which measures systemic inflammation; and fasting insulin, which detects metabolic dysfunction before glucose levels rise. Calculate your triglyceride-to-HDL ratio from the standard panel. A ratio above 3.5 indicates insulin resistance and small dense LDL particles. These markers detect subclinical cardiovascular risk years before standard panels show abnormalities. Lp(a) only needs to be tested once since levels are genetically determined and stable. The other markers should be monitored annually.